Moxifloxacin

證據等級: L5

預測適應症: 10 個

Moxifloxacin: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome

One-Sentence Summary

Moxifloxacin is a broad-spectrum fourth-generation fluoroquinolone antibiotic used clinically for bacterial infections including community-acquired pneumonia, complicated skin and skin-structure infections, and intra-abdominal infections. The TxGNN model predicts it may be effective for Polyclonal Hyperviscosity Syndrome, with 0 clinical trials and 0 publications currently supporting this direction. Notably, among all 10 predicted indications, Bubonic Plague (rank 10) emerges as the only candidate with a direct mechanistic basis and preclinical evidence (L3), while the majority of top-ranked predictions — including the #1 indication — lack any established clinical or mechanistic rationale.

Quick Overview

Item	Content
Original Indication	Not available from India regulatory data (clinically used for bacterial infections)
Predicted New Indication	Polyclonal Hyperviscosity Syndrome
TxGNN Prediction Score	99.98%
Evidence Level	L5
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the data sources queried. Based on established pharmacological knowledge, Moxifloxacin is a fluoroquinolone antibiotic that exerts bactericidal activity by inhibiting bacterial DNA gyrase (GyrA/GyrB) and topoisomerase IV — enzymes essential for DNA replication and transcription in bacteria. This mechanism is entirely directed at prokaryotic targets and has no recognized activity against human cellular pathways.

Polyclonal hyperviscosity syndrome arises from elevated plasma viscosity caused by an excess of polyclonal immunoglobulins, typically driven by inflammatory, autoimmune, or reactive conditions. There is no plausible direct mechanistic link between Moxifloxacin’s antibacterial mode of action and the immunoglobulin dysregulation underlying this syndrome. The TxGNN model likely generated this prediction through indirect knowledge graph connections — for instance, associating chronic bacterial infections as potential drivers of polyclonal immunoglobulin elevation — rather than any direct therapeutic pathway.

The high TxGNN score (99.98%) reflects model confidence based on graph topology and co-occurrence patterns, not clinical efficacy. Without mechanistic plausibility and with zero supporting evidence, this prediction should be treated as a graph artifact rather than a repurposing opportunity.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Moxifloxacin has no approved registrations in India in the current dataset. No authorization records, product names, dosage forms, or approved indications are available for review.

Safety Considerations

Drug Interactions (336 total interactions identified; Major-level interactions highlighted below):

Interacting Drug	Level	Clinical Concern
Hydrocortisone	Major	QT prolongation risk via electrolyte imbalance (hypokalemia)
Dexamethasone	Major	QT prolongation risk via electrolyte imbalance (hypokalemia)
Betamethasone	Major	QT prolongation risk via electrolyte imbalance (hypokalemia)
Triamcinolone	Major	QT prolongation risk via electrolyte imbalance (hypokalemia)
Bupropion	Major	Fluoroquinolones lower seizure threshold; additive CNS risk
Chlorpropamide	Major	Risk of hypoglycemia with fluoroquinolones

Representative moderate interactions (total 336 documented) include: Acarbose, Famotidine, Metformin, Pioglitazone, Alogliptin, Canagliflozin, Albiglutide, Loperamide, Acetylsalicylic acid, Balsalazide, Bisacodyl, Calcium Phosphate, Calcium acetate, and Potassium citrate.

The QT-prolongation risk associated with Moxifloxacin is clinically significant enough that it was selected as the positive control drug in a cardiac repolarisation study (NCT07023029), reinforcing that this is an established, well-characterized safety signal.

Please refer to the package insert for complete warnings and contraindications, as formal labeling data was not available in this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction (polyclonal hyperviscosity syndrome) has zero mechanistic plausibility, no clinical trial support, and no published literature — meeting only the L5 threshold (model prediction only). Proceeding with development based solely on a graph score is not justified.

Broader Landscape Across All 10 Predicted Indications:

Of the 10 predicted indications reviewed, the evidence quality is generally poor for repurposing purposes:

Rank	Indication	Evidence Level	Recommendation	Notes
1	Polyclonal hyperviscosity syndrome	L5	Hold	No mechanistic link, no evidence
2	Hyperamylasemia	L5	Hold	Potential safety concern (fluoroquinolones linked to pancreatitis)
3	Congenital analbuminemia	L5	Hold	Only incidental case report; no link to Moxifloxacin
4	Blood group incompatibility	L5	Hold	No mechanistic link; transfusion medicine domain
5	Premalignant hematological system disease	L5	Hold	Indirect immunodeficiency connection only
6	Monoclonal gammopathy	L4	Hold	Evidence reflects infection management in immunocompromised patients, not disease treatment
7	Hematological disease with peripheral neuropathy	L5	Hold	Safety concern: fluoroquinolones may worsen peripheral neuropathy
8	Congenital hematological disorder	L4	Hold	Moxifloxacin appears as QT positive control, not treatment
9	Hematopoietic and lymphoid system neoplasm	L5	Hold	No antitumour mechanism
10	Bubonic plague	L3	Research Question	Direct mechanistic link; multiple animal and in vitro PK/PD studies confirm activity against Yersinia pestis

Bubonic plague is the only indication warranting further attention. Moxifloxacin inhibits Y. pestis DNA gyrase with potent in vitro activity, and is already referenced in CDC bioterrorism response guidelines as an alternative to streptomycin. Multiple animal studies and in vitro PK/PD models confirm efficacy. The absence of human clinical trials reflects the ethical impracticality of conducting plague RCTs, not lack of scientific basis.

To advance the Bubonic Plague indication to the next stage, the following is needed:

Formal MOA data retrieval from DrugBank API (DG002 remediation)
Review of TFDA/India regulatory package insert for warnings and contraindications (DG001 remediation)
Assessment of regulatory pathway as a bioterrorism countermeasure (Emergency Use Authorization framework)
Systematic review of existing animal-to-human dose extrapolation data
QT monitoring protocol design given Moxifloxacin’s established cardiac safety signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.